Chimeric Therapeutics Ltd has released a press release.
Board & management commit to $1M placement and proposed spp
Filed with ASX ·
6ix hasn’t read this filing yet.
Chimeric Therapeutics Limited on 6ix
Story so far
Earlier from Chimeric Therapeutics
- New CLTX CAR technology patent protection in India & Israel
- Phase 1B brain cancer clinical trial approved for initiation
- CHM 1101 GBM Abstract Accepted for ASCO 2023 Presentation
- Positive pre-IND meeting with FDA for Phase 1 CAR T study
- Fourth dose cohort initiated in CHM 1101 Phase 1 trial
Later from Chimeric Therapeutics
- SPP offer documents issued to shareholders
- Launch of new Phase 1B Glioblastoma clinical trial
- Share purchase plan completed
- CHM secures up to A$12.6m through SPP and placements
- Positive data - CHM 0301 next-gen armoured NK cell platform
Follow Chimeric Therapeutics into a list and get an email when it puts out news.
Follow Chimeric Therapeutics